Insider Selling: Viewray Inc (VRAY) Major Shareholder Sells 185,948 Shares of Stock  Donald Scott | Aug 17th, 2018
Viewray Inc (NASDAQ:VRAY) major shareholder Orbimed Advisors Llc sold 185,948 shares of the company's stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $9.95, for a total value of $1,850,182.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website . Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Orbimed Advisors Llc also recently made the following trade(s): Get Viewray alerts: On Friday, August 10th, Orbimed Advisors Llc sold 1,368,796 shares of Viewray stock. The stock was sold at an average price of $9.97, for a total value of $13,646,896.12. On Tuesday, August 7th, Orbimed Advisors Llc sold 169,920 shares of Viewray stock. The stock was sold at an average price of $11.20, for a total value of $1,903,104.00.
Shares of VRAY stock opened at $9.97 on Friday. Viewray Inc has a 52-week low of $5.11 and a 52-week high of $13.21. The company has a quick ratio of 2.64, a current ratio of 3.33 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of $743.79 million, a price-to-earnings ratio of -9.59 and a beta of 1.24.
Viewray (NASDAQ:VRAY) last issued its quarterly earnings results on Friday, August 3rd. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.21) by ($0.09). Viewray had a negative return on equity of 353.05% and a negative net margin of 83.84%. The business had revenue of $16.44 million during the quarter, compared to analysts' expectations of $15.97 million. During the same quarter in the previous year, the company posted ($0.15) EPS. The company's quarterly revenue was up 2255.3% on a year-over-year basis. analysts expect that Viewray Inc will post -0.75 EPS for the current year.
A number of hedge funds have recently modified their holdings of the business. Voya Investment Management LLC boosted its holdings in shares of Viewray by 39.3% during the 2nd quarter. Voya Investment Management LLC now owns 19,006 shares of the company's stock valued at $132,000 after purchasing an additional 5,364 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Viewray by 1.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 412,625 shares of the company's stock valued at $2,857,000 after purchasing an additional 5,474 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Viewray by 0.4% during the 1st quarter. BlackRock Inc. now owns 1,859,946 shares of the company's stock valued at $11,960,000 after purchasing an additional 6,678 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Viewray by 15.6% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 61,260 shares of the company's stock valued at $394,000 after purchasing an additional 8,260 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Viewray by 209.7% during the 2nd quarter. Bank of America Corp DE now owns 14,710 shares of the company's stock valued at $101,000 after purchasing an additional 9,960 shares during the last quarter. Institutional investors and hedge funds own 84.42% of the company's stock.
A number of brokerages have issued reports on VRAY. BidaskClub lowered Viewray from a "buy" rating to a "hold" rating in a research note on Wednesday, August 8th. Mizuho reiterated a "buy" rating and issued a $13.00 price target on shares of Viewray in a research note on Monday, August 6th. ValuEngine upgraded Viewray from a "hold" rating to a "buy" rating in a research note on Wednesday, July 4th. Cantor Fitzgerald reiterated a "buy" rating and issued a $13.00 price target on shares of Viewray in a research note on Friday, May 11th. Finally, Jefferies Financial Group began coverage on Viewray in a research note on Tuesday, July 3rd. They issued a "buy" rating and a $12.00 price target for the company. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of "Buy" and an average price target of $12.58.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. Viewray Viewra